Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
This time last year none of us imagined we were about to go through a year like no other, and…
Continued Importance of CRAs Supporting Role for Patient Centric Trials
The COVID-19 world-wide pandemic has forced the clinical trial industry to make rapid changes in order to continue protecting participant…
CRAs Play a Supporting Role in Patient-Centric Trials
There is an ever-present desire in the clinical trial industry to practice ‘patient-centricity’. This practice is featured predominantly during the…
Overcome Oncology Clinical Trial Obstacles – 2019 Real World Evidence for 2020 and Beyond
Overall the clinical trial market is growing at a robust pace that is expected to continue into 2024, owing to…
Going Above-and-Beyond – What Can Your Specialized Oncology CRO Do for You?
Clinical research is a growing and fascinating field marked by increasing complexity and competitive surroundings. CROs can help their Sponsors…